Research Analysts Set Expectations for KYMR FY2026 Earnings

Key Points

• Brookline Capital Markets lowered its FY2026 EPS estimate for Kymera Therapeutics to a loss of $4.00 per share from $3.97, below the $3.90 consensus estimate, while maintaining a “Buy” rating.
• Kymera’s third-quarter results missed expectations, with a $1.32-per-share loss versus the $1.26 consensus and revenue of $1.35 million versus $3.28 million expected.
• Analyst sentiment remains favorable overall, with a “Moderate Buy” consensus rating and an average price target of $137.92; recent positive Phase 1 KT-579 results and higher targets from Truist and BTIG supported the outlook.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Brookline Capital Markets cut their FY2026 earnings per share (EPS) estimates for Kymera Therapeutics in a report issued on Thursday, October 29th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings of ($4.00) per share for the year, down from their previous estimate of ($3.97). Brookline Capital Markets currently has a "Buy" rating on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($3.90) per share. Brookline Capital Markets also issued estimates for Kymera Therapeutics' Q4 2026 earnings at ($1.34) EPS, FY2027 earnings at ($5.16) EPS, FY2028 earnings at ($6.07) EPS, FY2029 earnings at ($5.48) EPS and FY2030 earnings at ($5.84) EPS.

KYMR has been the topic of several other reports. Raymond James Financial reiterated an "outperform" rating on shares of Kymera Therapeutics in a report on Thursday. Truist Financial reissued a "buy" rating and issued a $150.00 price objective (up from $136.00) on shares of Kymera Therapeutics in a report on Friday. Royal Bank Of Canada raised their target price on Kymera Therapeutics from $112.00 to $116.00 and gave the stock a "sector perform" rating in a report on Friday. Piper Sandler reaffirmed an "overweight" rating and issued a $140.00 price target on shares of Kymera Therapeutics in a research note on Wednesday, September 23rd. Finally, TD Cowen upgraded Kymera Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $137.92.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $126.63 on Monday. The stock has a 50 day simple moving average of $114.93 and a 200 day simple moving average of $96.35. Kymera Therapeutics has a 1-year low of $55.66 and a 1-year high of $130.05. The stock has a market cap of $10.81 billion, a P/E ratio of -34.98 and a beta of 2.03.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 22.39%. The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $3.28 million. During the same quarter in the previous year, the firm earned ($0.94) earnings per share. The company's revenue for the quarter was up .0% compared to the same quarter last year.

Insider Activity

In other news, insider Brian Adams sold 6,371 shares of the business's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the sale, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the sale, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. This trade represents a 4.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 15.98% of the company's stock.

Institutional Trading of Kymera Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in KYMR. GAMMA Investing LLC increased its holdings in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company's stock valued at $52,000 after buying an additional 98 shares in the last quarter. IFP Advisors Inc boosted its stake in Kymera Therapeutics by 236.5% in the third quarter. IFP Advisors Inc now owns 737 shares of the company's stock valued at $82,000 after acquiring an additional 518 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Kymera Therapeutics by 56.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company's stock valued at $107,000 after acquiring an additional 463 shares during the last quarter. Nykredit A S purchased a new position in Kymera Therapeutics in the 2nd quarter worth about $207,000. Finally, Sterling Capital Management LLC lifted its stake in Kymera Therapeutics by 378.6% in the 3rd quarter. Sterling Capital Management LLC now owns 1,919 shares of the company's stock valued at $215,000 after acquiring an additional 1,518 shares in the last quarter.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, showing deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers, and a favorable safety profile. The data support continued development of the company’s immunology pipeline. Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: Truist Financial reaffirmed its “buy” rating and raised its price target from $136 to $150, implying further upside based on the current trading level. Truist Securities Adjusts Price Target on Kymera Therapeutics
• Positive Sentiment: BTIG Research raised its target from $134 to $139 and maintained a “buy” rating, adding to the favorable analyst sentiment.
• Neutral Sentiment: Kymera provided a Phase 1 update on the formulation study for KT-621, offering investors additional information on the program’s ongoing clinical development. KT-621 Formulation Study Update
• Neutral Sentiment: RBC increased its price target from $112 to $116 but retained a “sector perform” rating, signaling limited conviction at the current valuation.
• Negative Sentiment: Third-quarter results missed expectations: adjusted loss was $1.32 per share versus a $1.26 consensus loss, while revenue of $1.35 million was below the $3.28 million estimate. The net loss also widened year over year, highlighting ongoing cash-burn and execution risks. Kymera Therapeutics Q3 Net Loss Widens

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell's natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company's research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.